Trial
NCT01703208
A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Type 2 Diabetes Mellitus
Intervention
Omarigliptin
Why stopped
The study was terminated for business reasons and not due to any safety or efficacy concerns related to omarigliptin
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-06